[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,382,449
  • Shares Outstanding, K 59,472
  • Annual Sales, $ 54,030 K
  • Annual Income, $ -412,780 K
  • EBIT $ -476 M
  • EBITDA $ -478 M
  • 60-Month Beta 0.54
  • Price/Sales 43.60
  • Price/Cash Flow N/A
  • Price/Book 2.08

Options Overview Details

View History
  • Implied Volatility 65.84% (-1.99%)
  • Historical Volatility 59.97%
  • IV Percentile 67%
  • IV Rank 10.95%
  • IV High 254.54% on 11/18/25
  • IV Low 42.64% on 02/18/26
  • Expected Move (DTE 31) 4.72 (11.78%)
  • Put/Call Vol Ratio 0.43
  • Today's Volume 420
  • Volume Avg (30-Day) 1,017
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 42,366
  • Open Int (30-Day) 42,450
  • Expected Range 35.34 to 44.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.86
  • Number of Estimates 4
  • High Estimate $-1.62
  • Low Estimate $-2.01
  • Prior Year $-1.93
  • Growth Rate Est. (year over year) +3.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.30 +16.79%
on 06/22/26
44.09 -9.14%
on 07/07/26
+5.90 (+17.27%)
since 06/18/26
3-Month
24.29 +64.92%
on 04/27/26
44.09 -9.14%
on 07/07/26
+12.99 (+47.99%)
since 04/20/26
52-Week
22.24 +80.13%
on 11/19/25
46.00 -12.91%
on 11/18/25
+0.06 (+0.15%)
since 07/18/25

Most Recent Stories

More News
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in sickle...

AGIO : 40.06 (+1.14%)
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

FDA’s PDUFA goal date is November 1, 2026 If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE...

AGIO : 40.06 (+1.14%)
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 40.06 (+1.14%)
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects New analyses showed patients in mitapivat arm had clinically...

AGIO : 40.06 (+1.14%)
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement diversifies Agios’ rare hematology portfolio with expansion into immune thrombocytopenia,...

AGIO : 40.06 (+1.14%)
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was well tolerated, with no new safety signals observed CAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE)...

AGIO : 40.06 (+1.14%)
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable...

AGIO : 40.06 (+1.14%)
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia Mitapivat is now approved for thalassemia in the U.S.,...

AGIO : 40.06 (+1.14%)
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances

Agios Pharmaceuticals (NASDAQ:AGIO) executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently submitted...

AGIO : 40.06 (+1.14%)
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing...

AGIO : 40.06 (+1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 41.29
2nd Resistance Point 40.89
1st Resistance Point 40.48
Last Price 40.06
1st Support Level 39.67
2nd Support Level 39.27
3rd Support Level 38.86

See More

52-Week High 46.00
Last Price 40.06
Fibonacci 61.8% 36.92
Fibonacci 50% 34.12
Fibonacci 38.2% 31.32
52-Week Low 22.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.